10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group
Michael Lübbert(University of Freiburg), Gerwin Huls(University Medical Center Groningen), Mario Luppi(University of Modena and Reggio Emilia), Robin Foà(Sapienza University of Rome), Nicole Blijlevens(Radboud University Nijmegen), Aniek de Graaf(Radboud University Nijmegen), Walter J. F. M. van der Velden(Radboud University Nijmegen), Frédéric Baron(University of Liège), Heiko Becker(University of Freiburg), Joop H. Jansen(Radboud University Nijmegen), Eduardus F. M. Posthuma(Leiden University Medical Center), Sylvain Chantepie(Centre Hospitalier Universitaire de Caen Normandie), Fabio Efficace(Fondazione Gimema Onlus), Mels Hoogendoorn(Medisch Centrum Leeuwarden), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ollivier Legrand(Inserm), Stephan Fuhrmann(Helios Hospital Berlin-Buch), Andreas Neubauer(RWTH Aachen University), Stefan Suciu(European Organisation for Research and Treatment of Cancer), Radovan Vrḫovac(University Hospital Centre Zagreb), Daniëlle van Lammeren‐Venema(Haga Hospital), Emanuele Ammatuna(University Medical Center Groningen), Laimonas Griškevičius(Vilnius University), Marian Stevens‐Kroef(Radboud University Nijmegen), Sergio Amadori(Polyclinic Medical Center), Richard Noppeney(Essen University Hospital), Ulrich Dührsen(Essen University Hospital), Ralph Wäsch(University of Freiburg), Jean Pierre Vilque(Centre Hospitalier Universitaire de Caen Normandie), Martina Crysandt(RWTH Aachen University), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Pierre W. Wijermans(Radboud University Nijmegen), Stéphanie Antunes(European Organisation for Research and Treatment of Cancer), Adriano Venditti(University of Rome Tor Vergata), Anna Candoni(University of Udine)
Cited by 1
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k